Safety and tolerability of injectable Rilpivirine LA in HPTN 076: A phase 2 HIV pre-exposure prophylaxis study in women

Background: Daily oral TDF/FTC is protective against HIV infection when used for pre-exposure prophylaxis (PrEP). However, daily adherence to oral PrEP is difficult for many; therefore, finding alternative PrEP strategies remains a priority. HPTN 076 evaluated the long-acting injectable form of rilp...

Full description

Bibliographic Details
Main Authors:	L.G. Bekker, S. Li, S. Pathak, E.E. Tolley, M.A. Marzinke, J.E. Justman, N.M. Mgodi, M. Chirenje, S. Swaminathan, A. Adeyeye, J. Farrior, C.W. Hendrix, E. Piwowar-Manning, P. Richardson, S.H. Eshelman, H. Redinger, P. Williams, N.D. Sista
Format:	Article
Language:	English
Published:	Elsevier 2020-04-01
Series:	EClinicalMedicine
Online Access:	http://www.sciencedirect.com/science/article/pii/S258953702030047X

Internet

http://www.sciencedirect.com/science/article/pii/S258953702030047X

Safety and tolerability of injectable Rilpivirine LA in HPTN 076: A phase 2 HIV pre-exposure prophylaxis study in women

Internet

Similar Items